Premo Pharm. Labs. v. Pfizer Pharm., Inc.

Decision Date05 March 1979
Docket NumberNo. 78 Civ. 5234 (MP).,78 Civ. 5234 (MP).
Citation465 F. Supp. 1281
PartiesPREMO PHARMACEUTICAL LABORATORIES, INC., Plaintiff, v. PFIZER PHARMACEUTICALS, INC., Defendant.
CourtU.S. District Court — Southern District of New York

Kirschstein, Kirschstein, Ottinger & Cobrin, New York City, for plaintiff, by Peter T. Cobrin, New York City.

Kaye, Scholer, Fierman, Hays & Handler, New York City, for defendant, by David Klingsberg, New York City.

OPINION

POLLACK, District Judge.

Premo Pharmaceutical Laboratories, Inc., has sued for a declaratory judgment that two patents held by the defendant, Pfizer Pharmaceuticals, Inc., are invalid and not infringed by a drug product that Premo manufactures and sells. Pfizer has moved under Fed.R.Civ.P. 12(b)(1) and (6) to dismiss the complaint on the grounds that no actual controversy exists between the parties and therefore that the Court has no jurisdiction under the Declaratory Judgment Act, 28 U.S.C. § 2201.

For the reasons shown hereafter the complaint must be dismissed.

The requirements in this Circuit for an actual controversy under the Declaratory Judgment Act in a patent case were most recently summarized by Judge Lasker:

In patent matters, case law has established two prerequisites to a finding of an actual controversy: (1) the owner of the patent (usually the defendant) must have charged plaintiff with infringement or at least threatened an infringement suit, either directly or indirectly; (2) the plaintiff must actually have produced or prepared to produce the accused article. (Mine Safety Appliance Co. v. Energetics Science, Inc., 416 F.Supp. 530, 531 (S.D.N. Y.1976)).

See also Muller v. Olin Mathieson Chemical Corp., 404 F.2d 501 (2d Cir. 1968); Dr. Beck and Co. v. General Electric Co., 317 F.2d 538 (2d Cir. 1963); Wembley, Inc. v. Superba Cravats, Inc., 315 F.2d 87 (2d Cir. 1963). There is no question that the second requirement is met here.

Premo argues that the requirement of a charge of infringement has been so far liberalized that "a declaratory action for the invalidity of a patent is justiciably ripe ... if the plaintiff has a reasonable apprehension that it will face an infringement suit or the threat of one if it continues the activity in question," even if the defendant has not charged infringement.

The requirement of a charge of infringement has been very liberally interpreted. A charge has been found in threatening letters to the plaintiff, or to one of its customers, potential customers, or licensees; in suits against a licensee or a manufacturer of a similar product; and in notices to the trade; as well as in actual suits against the declaratory plaintiff for infringement. See, e. g., Blackman v. Hadron, Inc., 450 F.2d 781 (2d Cir. 1971) (suit for contributory infringement); Broadview Chemical Corp. v. Loctite Corp., 417 F.2d 998 (2d Cir. 1969), cert. denied, 397 U.S. 1064, 90 S.Ct. 1502, 25 L.Ed.2d 686 (1970) (letters to plaintiff and its customers); Muller v. Olin Mathieson Chemical Corp., supra, (previous litigation between the parties over same patents; letter to plaintiff's licensee); Joseph Bancroft & Sons Co. v. Spunize Co., 268 F.2d 522 (2d Cir. 1959) (suit against plaintiff's licensee); Dewey & Almy Chemical Co. v. American Anode, Inc., 137 F.2d 68 (3d Cir.), cert. denied, 320 U.S. 761, 64 S.Ct. 70, 88 L.Ed. 454 (1943) (suit against manufacturer of similar product); Lances v. Letz, 115 F.2d 916 (2d Cir. 1940) (letter to plaintiff); Leach v. Ross Heating & Mfg. Co., 104 F.2d 88 (2d Cir. 1939) (notice to trade; threats to prospective customers); Mine Safety Appliance Co., supra, (letter and oral communications to plaintiff); Volkswagen of America, Inc. v. Engelhard Minerals & Chemicals Corp., 401 F.Supp. 1210 (S.D.N.Y.1975) (letter to plaintiff); Blessings Corp. v. Altman, 373 F.Supp. 802 (S.D.N.Y.1974) (charge of infringement in earlier arbitration between parties); Wallace & Tiernan, Inc. v. General Electric Co., 291 F.Supp. 217 (S.D.N.Y.1968) (threats to defendant's licensees).

A careful reading of the cases satisfies the Court that an action taken by the defendant with respect to the challenged patent will be considered a charge of infringement if it inspires a reasonable apprehension of suit, not that a reasonable apprehension of suit itself creates an actual controversy, whether or not it was inspired by action of the defendant.

In Super Products Corp. v. D P Way Corp., 546 F.2d 748 (7th Cir. 1977), "the defendant's officers stated to prospective investors and customers of the plaintiff that the defendant would bring infringement litigation if any competitors, including the plaintiff, were to infringe its patent rights." Id. at 753-54. The Seventh Circuit stated:

To establish an actual controversy in an action challenging the validity of a patent, the plaintiff must disclose conduct on the part of the defendant that makes reasonable the plaintiff's apprehension that it will face an infringement suit or the threat of one if it commences, or continues the activity in question. (Id. at 753; emphasis added).

The Court held that the statements of the defendant's officers created a reasonable apprehension of suit and therefore created an actual controversy. Similarly, in Sherwood Medical Industries, Inc. v. Deknatel, Inc., 512 F.2d 724 (8th Cir. 1975), the Court held that an actual controversy was created by statements of an employee of the defendant that the plaintiff's product would infringe the defendant's patent. Id. at 726. Again the Court made clear that the reasonable apprehension must arise from action of the defendant:

An "actual controversy" exists if there has been a charge of infringement. However, such a charge need not be express and can be found in any conduct
...

To continue reading

Request your trial
8 cases
  • SK&F, Co. v. Premo Pharmaceutical Laboratories, Inc.
    • United States
    • U.S. Court of Appeals — Third Circuit
    • June 12, 1980
    ...E. R. Squibb & Sons v. Premo Pharm. Labs., Inc., 195 U.S.P.Q. 545, 547-48 (S.D.N.Y.1977); see Premo Pharm. Labs., Inc. v. Pfizer Pharm., Inc., 465 F.Supp. 1281, 1283-84 (S.D.N.Y.1979) (patent infringement issue).2 The survey, conducted over three days, involved having the various prescripti......
  • Mutual Pharmaceutical Co., Inc. v. Pfizer, Inc.
    • United States
    • U.S. District Court — District of Columbia
    • March 24, 2004
    ...a reasonable apprehension of suit even when other litigation was pending between the two parties); Premo Pharm. Labs. v. Pfizer Pharms., Inc., 465 F.Supp. 1281, 1283-84 (S.D.N.Y.1979) (holding that a history of litigiousness by the defendant does not, by itself, support a reasonable apprehe......
  • Hogs & Heroes Found. Inc. v. Heroes, Inc.
    • United States
    • U.S. District Court — District of Maryland
    • August 18, 2016
    ...establishes litigiousness sufficient to convert licensing negotiations into a threat of suit."); Premo Pharm. Labs., Inc. v. Pfizer Pharm. Labs., Inc. , 465 F.Supp. 1281 (S.D.N.Y.1979) (thirty-eight lawsuits over 17 years did not create an actual controversy).Along a similar vein, HHF makes......
  • Indium Corp. of America v. Semi-Alloys, Inc.
    • United States
    • U.S. District Court — Northern District of New York
    • July 1, 1983
    ...However, the source of that fear or apprehension must be in the patentee's statements or conduct. Premo Pharm. Labs. v. Pfizer Pharm., Inc., 465 F.Supp. 1281 (S.D.N.Y.1979). "A reasonable apprehension alone, if not inspired by defendant's actions, does not give rise to an actual controversy......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT